Because CSF1/CSF1R signalling drives PVNS and targeted inhibitors such as vimseltinib achieve significant tumour regression and functional improvement (23), similar targeted approaches might be explored for diffuse synovial proliferative disorders. Here, CSF1R is linked to neoplasm.